© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 21st 2021, 2:00pm
In an abstract presented at this year’s American Academy of Neurology annual meeting, patients with multiple sclerosis (MS) taking ocrelizumab had less of an immune reaction to infection with SARS-CoV-2, the virus that causes COVID-19.
April 19th 2021, 3:30pm
Compared with disease-modifying therapy (DMT), age, insurance status, and Hispanic ethnicity were shown to more accurately predict likelihood of COVID-19 and hospitalization from it among individuals with multiple sclerosis (MS).
April 16th 2021, 4:33pm
An online tool developed to facilitate efficient patient-provider decisions on disease modifying drugs for multiple sclerosis (MS) ran into several challenges and warrants further study.
April 13th 2021, 6:55pm
A prospective bicentric cohort study among individuals with relapsing-remitting multiple sclerosis (RRMS) showed that 32% developed at least 1 skin-related adverse reaction following cladribine administration.
April 10th 2021, 12:00pm
The advent of both new diagnostic criteria and treatments have necessitated a reevaluation of fatigue among individuals who have multiple sclerosis, investigators say.
April 7th 2021, 6:58pm
Because health literacy can have different meanings for patients with different diseases, this review aimed to crystalize a definition in patients with multiple sclerosis (MS) and emphasize its importance in care planning.
April 1st 2021, 11:00am
Among patients with multiple sclerosis, there is a 16% greater risk of infection, including for lower respiratory and herpes virus infections, after administration of fingolimod.
March 30th 2021, 1:50pm
With most current therapies for patients with multiple sclerosis (MS) targeting disease progression, a recent review evaluated transcranial direct current stimulation’s ability to improve certain disease symptoms.
March 26th 2021, 9:04pm
Investigators aimed to close the knowledge gap on interindividual variability in cognitive evaluation outcomes by considering both cognitive impairment and mood disorders to better prediction accuracy.
March 24th 2021, 6:49pm
With many patients with multiple sclerosis (MS) increasingly turning to herbal drugs and supplements to treat their disease, for which there is no cure, a recent review evaluated the safety of these alternative therapies.